Amylyx Pharmaceuticals (AMLX) Payables: 2021-2025
Historic Payables for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $5.3 million.
- Amylyx Pharmaceuticals' Payables rose 259.05% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year decrease of 67.21%. This contributed to the annual value of $2.9 million for FY2024, which is 86.68% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Payables of $5.3 million as of Q3 2025, which was up 62.08% from $3.3 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Payables ranged from a high of $24.7 million in Q2 2023 and a low of $1.5 million during Q3 2024.
- For the 3-year period, Amylyx Pharmaceuticals' Payables averaged around $9.8 million, with its median value being $5.3 million (2025).
- In the last 5 years, Amylyx Pharmaceuticals' Payables crashed by 86.68% in 2024 and then soared by 259.05% in 2025.
- Amylyx Pharmaceuticals' Payables (Quarterly) stood at $4.4 million in 2021, then spiked by 43.12% to $6.3 million in 2022, then surged by 252.58% to $22.1 million in 2023, then slumped by 86.68% to $2.9 million in 2024, then soared by 259.05% to $5.3 million in 2025.
- Its Payables stands at $5.3 million for Q3 2025, versus $3.3 million for Q2 2025 and $4.8 million for Q1 2025.